Takhzyro OverviewLanadelumab (INN) (trade name Takhzyro) is a human monoclonal antibody (class IgG1 kappa) that targets plasma kallikrein (pKal) in order to promote prevention of angioedema in patients with hereditary angioedema. In phase 1 clinical trials Lanadelumab was well tolerated and was reported to reduce cleavage of kininogen in the plasma of patients with hereditary angioedema and decrease the number of patients experiencing...
Read more Takhzyro Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Lanadelumab
Recent Takhzyro Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 300mg/ml(150mg/ml)
NDC Database Records for Takhzyro: (1 result)Sorted by National Drug Code
- 47783-644 Takhzyro 300 mg/2ml Subcutaneous Injection, Solution by Dyax Corp.